Acute Treatment of Migraines
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Study Information
Condition | Migraines |
---|---|
Phase | III |
Conquest Research needs volunteers for a migraine trial evaluating a nasal medication designed to help treat patients suffering from acute migraine attacks. You may qualify if you:
Are between the age of 18 and 65
Have at least a 1-year history of migraines
Experience 2 to 8 migraine headache attacks of moderate to severe intensity per month
Eligible participants will receive study-related care at no cost. Compensation for time and travel may be available. No medical insurance is required for participation.